Of NCE SUVN-3031 for treatment of Alzheimer's Disease
Suven Life Sciences announced that the Company's NCE SUVN-3031 has commenced Phase 1 clinical trial in USA. SUVN-G3031 - A potent, selective, brain penetrant and orally active Histamine H3 antagonist for the treatment of cognitive dysfunction associated with Alzheimer's Disease / Schizophrenia has completed all the preclinical, safety and early toxicological studies, GLP toxicological studies and was submitted for Investigational New Drug Application (IND) to conduct Phase 1 clinical trial with the indication for Cognition in Alzheimer's Disease under 505(1) of the Federal Food, Drug and Cosmetic Act (FDCA) which was assigned an IND number 123179.Powered by Capital Market - Live News
